The Use of Canakinumab, a Novel IL-1β Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease - Concepedia

Concepedia

Publication | Closed Access

The Use of Canakinumab, a Novel IL-1β Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease

88

Citations

15

References

2012

Year

Apostolos Kontzias, Petros Efthimiou

Seminars in Arthritis and Rheumatism

InflammationRefractory Adult-onsetAnti-inflammatoryAutoimmune DiseaseMedicineImmunologyImmune RegulationAutoimmunityPharmacotherapyImmunotherapyPharmacologyImmune Dysregulation

References

	Year	Citations

Page 1